USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Ysios Capital, Spain’s largest and leading European venture capital firm specialized in the biotechnology sector, announces today that it has closed its third fund, Ysios BioFund 3 (YBF 3) at 216 million euros ($260 million). 26 May 2021
Swiss clinical-stage biotech Numab Therapeutics today announced the closing of a 100 million Swiss franc (~$110 million) Series C financing. 20 May 2021
Launched in February 2019 with $60 million financing, US biotech HiberCell today announced that it has completed a Series B financing round for gross proceeds of $67.4 million. 20 May 2021
Texas, USA-based molecular science and artificial intelligence (AI) focused Caris Life Sciences has announced an $830 million growth equity round at a post-money valuation of $7.83 billion. 14 May 2021
Eikon Therapeutics, a pioneer in live-cell super-resolution microscopy and engineering for drug discovery, today announced that it has closed a $148 million Series A financing led by The Column Group with participation from Foresite Capital, Innovation Endeavors and Lux Capital. 5 May 2021
USA-based Cocrystal Pharma saw its shares rocket 73% to $2.14 by close of trading yesterday, after it announced progress in developing broad-spectrum antiviral drug candidates that target coronaviruses including SARS-CoV-2, the coronavirus that causes COVID-19. 5 May 2021
Spanish plasma specialist Grifols is to establish a global R&D hub in Andorra, focused on the human immune system and the potential for novel immune therapies. 28 April 2021
Guernsey and Switzerland based Pureos Bioventure has announces the final closing of its first fund BB Pureos Bioventures LP with a committed capital of $205 million. 22 April 2021
UK endocrine diseases specialist Diurnal today said it has raised £20 million ($28 million) through a placing to fund the company’s pivotal Phase III trial for Efmody (hydrocortisone modified-release hard capsules), a drug formerly known as Chronocort, as a treatment for congenital adrenal hyperplasia in the US through to registration. 21 April 2021
Global non-profit partnership CARB-X is funding privately-held UK company Phico Therapeutics to develop a new intravenous engineered bacteriophage drug to treat ventilator-associated pneumonia caused by Pseudomonas aeruginosa. 19 April 2021
US biotech Adagio Therapeutics says it has completed a $336 million Series C financing led by RA Capital Management, with participation from new investors, including Redmile Group, Federated Hermes, Foresite Capital, ArrowMark Partners, PremjiInvest, and another leading healthcare investor. 19 April 2021
For biotech companies, the prospect of receiving non-dilutive, non-recourse funding to advance their assets even through the early stages of clinical development may sound too good to be true. 16 April 2021
Cambridge, UK-based biotech Alchemab Therapeutics today announced the completion of a £60 million ($82 million) Series A financing round. 15 April 2021
AELIS FARMA, a privately-held French biotech specializing in the treatment of brain disorders, has announced a boost for the Improving Cognition in Down Syndrome (ICOD) project. 9 April 2021
US biotech Ventus Therapeutics today announced a $100 million Series B financing led by RA Capital Management, with the proceeds to be used to advance its pipeline of small-molecule medicines against traditionally undruggable targets. 8 April 2021
Hutchison China MediTech, also known as Hutchmed, has announced a private placement of $100 million of funds from Baring Private Equity Asia (BPEA). 8 April 2021
Multinational companies (MNCs) must evolve their strategies with a fast-paced China to succeed in the highly competitive market, said company representatives at the two-day 2021 China healthcare investment conference on March 24 in Shanghai. 6 April 2021
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news